Treatment of prostate carcinoma cells with the selective CB1 agonist WIN55,212–2 led to a decrease in migration with a significant diminishing of RhoA activity, while treatment with CB1 selective antagonist AM251 showed a significant increase in RhoA activity. Here, RHOA is linked to prostate carcinoma.